Literature DB >> 18582181

Utility of objective measures of activity and attention in the assessment of therapeutic response to stimulants in children with attention-deficit/hyperactivity disorder.

Martin H Teicher1, Ann Polcari, Cynthia E McGreenery.   

Abstract

BACKGROUND AND
PURPOSE: Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent disorder that can respond dramatically to medication, if dose is appropriately titrated. Studies suggest that computer measures of attention cannot be used for titration as they show improvement on doses too low to produce clinical benefits. We assessed whether measures of motor activity and attention using the McLean Motion Attention Test (M-MAT) could identify doses associated with optimal clinical response.
METHODS: Eleven boys (9.6 +/- 1.8 years), receiving treatment with methylphenidate, and meeting DSM-IV criteria for ADHD, participated in this triple-blind (parent, child, rater), within-subject, efficacy study. Subjects received 1 week each of placebo, low (0.4 mg/kg), medium (0.8 mg/kg), and high (1.5 mg/kg) daily doses of methylphenidate. Parents rated response using an index of clinical global improvement.
RESULTS: In 9/11 subjects, the dose that produced the best improvement on M-MAT measures was also the dose that produced the best clinical outcome (p < 10(5)). Parents rated response to this dose significantly better than response to previously prescribed treatment. Objective measures of primarily activity and secondarily attention responded to treatment in a manner concordant with clinical ratings, suggesting that these measures have ecological validity, and the potential to facilitate medication management and titration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582181      PMCID: PMC2935830          DOI: 10.1089/cap.2007.0090

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  31 in total

1.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

2.  Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.

Authors:  Bradley N Bohnstedt; William G Kronenberger; David W Dunn; Ann L Giauque; Elisabeth A Wood; Mary E Rembusch; Deborah Lafata
Journal:  J Atten Disord       Date:  2005-05       Impact factor: 3.256

3.  The neural bases of momentary lapses in attention.

Authors:  D H Weissman; K C Roberts; K M Visscher; M G Woldorff
Journal:  Nat Neurosci       Date:  2006-06-11       Impact factor: 24.884

4.  Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.

Authors:  Joseph Biederman; Haitao Gao; Ann K Rogers; Thomas J Spencer
Journal:  Biol Psychiatry       Date:  2006-06-27       Impact factor: 13.382

5.  Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry.

Authors:  M H Teicher; C M Anderson; A Polcari; C A Glod; L C Maas; P F Renshaw
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 6.  Effectiveness outcomes in attention-deficit/hyperactivity disorder.

Authors:  Margaret D Weiss; Kenneth Gadow; Michael B Wasdell
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

7.  Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens.

Authors:  Martin H Teicher; Ann Polcari; Mary Foley; Elizabeth Valente; Cynthia E McGreenery; Wei-Wei Chang; Gordon McKay; Kamal K Midha
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-08       Impact factor: 2.576

Review 8.  Attention-deficit hyperactivity disorder.

Authors:  Joseph Biederman; Stephen V Faraone
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

9.  Determinants of compliance with methylphenidate therapy in children.

Authors:  Jacqueline G Hugtenburg; Ivo Witte; Eibert R Heerdink
Journal:  Acta Paediatr       Date:  2006-12       Impact factor: 2.299

10.  Is OPTAx useful for monitoring the effect of stimulants on hyperactivity and inattention? A brief report.

Authors:  Janne Tabori-Kraft; Merete Juul Sørensen; Martin Kaergaard; Søren Dalsgaard; Per Hove Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2007-05-02       Impact factor: 4.785

View more
  12 in total

1.  Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials.

Authors:  Bjørn E Ramtvedt; Elisabeth Røinås; Henning S Aabech; Kjetil S Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-09       Impact factor: 2.576

Review 2.  Cross-species assessments of motor and exploratory behavior related to bipolar disorder.

Authors:  Brook L Henry; Arpi Minassian; Jared W Young; Martin P Paulus; Mark A Geyer; William Perry
Journal:  Neurosci Biobehav Rev       Date:  2010-04-14       Impact factor: 8.989

Review 3.  The clinical utility of the continuous performance test and objective measures of activity for diagnosing and monitoring ADHD in children: a systematic review.

Authors:  Charlotte L Hall; Althea Z Valentine; Madeleine J Groom; Gemma M Walker; Kapil Sayal; David Daley; Chris Hollis
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-11-30       Impact factor: 4.785

4.  Identification of a circuit-based endophenotype for familial depression.

Authors:  Marc J Dubin; Marc Dubin; Myrna M Weissman; Myrna Weissman; Dongrong Xu; Ravi Bansal; Xuejun Hao; Jun Liu; Virginia Warner; Bradley S Peterson; Bradley Peterson
Journal:  Psychiatry Res       Date:  2012-04-18       Impact factor: 3.222

5.  Locomotor activity measures in the diagnosis of attention deficit hyperactivity disorder: Meta-analyses and new findings.

Authors:  Lourdes García Murillo; Samuele Cortese; David Anderson; Adriana Di Martino; Francisco Xavier Castellanos
Journal:  J Neurosci Methods       Date:  2015-03-11       Impact factor: 2.390

6.  A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men.

Authors:  William Perry; Arpi Minassian; Martin P Paulus; Jared W Young; Meegin J Kincaid; Eliza J Ferguson; Brook L Henry; Xiaoxi Zhuang; Virginia L Masten; Richard F Sharp; Mark A Geyer
Journal:  Arch Gen Psychiatry       Date:  2009-10

7.  Objective Measures of Behavior Manifestations in Adult ADHD and Differentiation from Participants with Bipolar II Disorder, Borderline Personality Disorder, Participants with Disconfirmed ADHD as Well as Normative Participants.

Authors:  Hanna Edebol; Lars Helldin; Torsten Norlander
Journal:  Clin Pract Epidemiol Ment Health       Date:  2012-11-02

8.  A preliminary study of movement intensity during a Go/No-Go task and its association with ADHD outcomes and symptom severity.

Authors:  Fenghua Li; Yi Zheng; Stephanie D Smith; Frederick Shic; Christina C Moore; Xixi Zheng; Yanjie Qi; Zhengkui Liu; James F Leckman
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2016-12-12       Impact factor: 3.033

9.  The Impact of Methylphenidate on QbTest Performance of Children with ADHD: A Retrospective Clinical Study.

Authors:  Rajna Knez; Dejan Stevanovic; Salmir Nasic; Ana Doric; Elisabet Wentz
Journal:  Neuropsychiatr Dis Treat       Date:  2021-01-06       Impact factor: 2.570

Review 10.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.